...
首页> 外文期刊>The Japanese journal of antibiotics >Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria
【24h】

Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria

机译:头孢唑仑对各种临床分离株的抗菌活性的售后监测--I。革兰氏阳性菌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

As a post-marketing surveillance, the in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates were yearly evaluated and compared with those of other cephems, oxacephems, penicillins, and carbapenems. Changes in the bacterial sensitivity for CZOP were also evaluated with the resistance ratio calculated with breakpoint MIC. Sixteen species (1,913 strains) of Gram-positive bacteria were isolated from the clinical materials annually collected from 1996 to 2000, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n = 178), methicillin-resistant S. aureus (MRSA; n = 199), methicillin-susceptible Staphylococcus epidermidis (MSSE; n = 98), methicillin-resistant S. epidermidis (MRSE; n = 164), Staphylococcus haemolyticus (n = 72), Staphylococcus saprophyticus (n = 28), Enterococcus faecalis (n = 206), Enterococcus faecium (n = 91), Enterococcus avium (n = 72), Streptococcus pyogenes (n = 133), Streptococcus agalactiae (n = 138), penicillin-susceptible Streptococcus pneumoniae (PSSP; n = 133), penicillin-intermediate resistant S. pneumoniae (PISP; n = 100), penicillin-resistant S. pneumoniae (PRSP; n = 29), Streptococcus milleri group (n = 135) and Peptostreptococcus spp. (n = 137). CZOP possessed comparable antibacterial activities against MSSA and MSSE to other cephems, and was also effective on MRSE but not on MRSA. An antibacterial activity of CZOP against S. saprophyticus was comparable to or higher than other cephems. CZOP, however, did not indicate an antibacterial activity against S. haemolyticus, just like other cephems. An antibacterial activity of CZOP against E. faecalis was comparable to cefpirome (CPR) and higher than other cephems. No antibacterial activity of CZOP against E. faecium and E. avium was observed, just like other drugs. An antibacterial activity of CZOP against S. pyogenes was as potent as that of cefotiam (CTM), cefepime (CFPM) and CPR, and that against S. agalactiae was also preferable. CZOP and other cephems also had a preferable antibacterial activity against S. milleri group that was most sensitive to benzylpenicillin. An antibacterial activity of CZOP against Peptostreptococcus spp. was preferable but weaker than that of cefazolin, CTM and cefmetazole. The resistance ratio estimated with breakpoint MIC of CZOP was 96.5% in MRSA, 93.1% in PRSP, 60.0% in PISP, 40.3% in S. haemolyticus, 22.3% in E. faecalis, and 15.9% in MRSE. Those resistance ratios were similar to those for CFPM, but E. faecalis showed 90.8% resistance for CFPM. The difference in the resistance ratio of E. faecalis demonstrated that CZOP successfully maintained its antibacterial activity against this species. In conclusion, no remarkable annual change in the antibacterial activities of CZOP against the Gram-positive bacteria was observed. The sensitivities of PISP and PRSP to CZOP, however, was suggested to be decreasing.
机译:作为售后监测,每年评估头孢制剂的头孢唑仑(CZOP)对各种临床分离株的体外抗菌活性,并将其与其他头孢,草丁香,青霉素和碳青霉烯类进行比较。还用通过断点MIC计算的抗性比评估了对CZOP的细菌敏感性的变化。从1996年至2000年,每年从临床资料中分离出16种革兰氏阳性细菌(1,913株),包括耐甲氧西林的金黄色葡萄球菌(MSSA; n = 178),耐甲氧西林的金黄色葡萄球菌(MRSA; n = 199),对甲氧西林敏感的表皮葡萄球菌(MSSE; n = 98),对耐甲氧西林的表皮葡萄球菌(MRSE; n = 164),溶血性葡萄球菌(n = 72),腐生葡萄球菌(n = 28),粪肠球菌(n = 28) n = 206),粪肠球菌(n = 91),禽肠球菌(n = 72),化脓性链球菌(n = 133),无乳链球菌(n = 138),青霉素易感性肺炎链球菌(PSSP; n = 133),耐青霉素中间肺炎链球菌(PISP; n = 100),耐青霉素肺炎链球菌(PRSP; n = 29),链球菌Milleri组(n = 135)和Peptostreptococcus spp。 (n = 137)。 CZOP具有对抗MSSA和MSSE的抗菌活性,可与其他Cephems媲美,并且对MRSE有效,但对MRSA无效。 CZOP对腐生链球菌的抗菌活性与其他头孢类相当或更高。但是,CZOP并不像其他头孢类一样对溶血链球菌具有抗菌活性。 CZOP对屎肠球菌的抗菌活性可与头孢哌啶(CPR)相媲美,并且比其他头孢更高。像其他药物一样,未观察到CZOP对屎肠球菌和鸟肠杆菌的抗菌活性。 CZOP对化脓性链球菌的抗菌活性与头孢替安(CTM),头孢吡肟(CFPM)和CPR一样有效,对无乳链球菌的抗菌活性也较好。 CZOP和其他头孢菌素还具有对S. milleri基团的最佳抗菌活性,该菌对苄青霉素最敏感。 CZOP对Peptostreptococcus spp的抗菌活性。比头孢唑林,CTM和头孢美唑更好,但较弱。用CZOP的断点MIC估算的耐药率在MRSA中为96.5%,在PRSP中为93.1%,在PISP中为60.0%,在溶血链球菌中为40.3%,在粪肠球菌中为22.3%,在MRSE中为15.9%。这些阻力比与CFPM相似,但粪肠球菌对CFPM的阻力为90.8%。粪肠球菌的抗药性比率的差异表明,CZOP成功地保持了其对这一物种的抗菌活性。总之,未观察到CZOP对革兰氏阳性细菌的抗菌活性有明显的年度变化。但是,PISP和PRSP对CZOP的敏感性正在降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号